Relationship between donor-derived cell-free DNA and tissue-based rejection-related transcripts in heart transplantation
- PMID: 38373559
- DOI: 10.1016/j.healun.2024.02.011
Relationship between donor-derived cell-free DNA and tissue-based rejection-related transcripts in heart transplantation
Abstract
Background: Endomyocardial biopsy (EMB)-based traditional microscopy remains the gold standard for the detection of cardiac allograft rejection, despite its limitation of inherent subjectivity leading to inter-reader variability. Alternative techniques now exist to surveil for allograft injury and classify rejection. Donor-derived cell-free DNA (dd-cfDNA) testing is now a validated blood-based assay used to surveil for allograft injury. The molecular microscope diagnostic system (MMDx) utilizes intragraft rejection-associated transcripts (RATs) to classify allograft rejection and identify injury. The use of dd-cfDNA and MMDx together provides objective molecular insight into allograft injury and rejection. The aim of this study was to measure the diagnostic agreement between dd-cfDNA and MMDx and assess the relationship between dd-cfDNA and MMDx-derived RATs, which may provide further insight into the pathophysiology of allograft rejection and injury.
Methods: This is a retrospective observational study of 156 EMB evaluated with traditional microscopy and MMDx. All samples were paired with dd-cfDNA from peripheral blood before EMB (up to 9 days). Diagnostic agreement between traditional histopathology, MMDx, and dd-cfDNA (threshold of 0.20%) was compared for assessment of allograft injury. In addition, the relationship between dd-cfDNA and individual RAT expression levels from MMDx was evaluated.
Results: MMDx characterized allograft tissue as no rejection (62.8%), antibody-mediated rejection (ABMR) (26.9%), T-cell-mediated rejection (TCMR) (5.8%), and mixed ABMR/TCMR (4.5%). For the diagnosis of any type of rejection (TCMR, ABMR, and mixed rejection), there was substantial agreement between MMDx and dd-cfDNA (76.3% agreement). All transcript clusters (group of gene sets designated by MMDx) and individual transcripts considered abnormal from MMDx had significantly elevated dd-cfDNA. In addition, a positive correlation between dd-cfDNA levels and certain MMDx-derived RATs was observed. Tissue transcript clusters were correlated with dd-cfDNA scores, including DSAST, GRIT, HT1, QCMAT, and S4. For individual transcripts, tissue ROBO4 was significantly correlated with dd-cfDNA in both nonrejection and rejection as assessed by MMDx.
Conclusions: Collectively, we have shown substantial diagnostic agreement between dd-cfDNA and MMDx. Furthermore, based on the findings presented, we postulate a common pathway between the release of dd-cfDNA and expression of ROBO4 (a vascular endothelial-specific gene that stabilizes the vasculature) in the setting of antibody-mediated rejection, which may provide a mechanistic rationale for observed elevations in dd-cfDNA in AMR, compared to acute cellular rejection.
Keywords: acute cellular rejection; alograft rejection; antibody-mediated rejection; donor-derived cell-free DNA; gene expression profile; heart transplant; molecular microscopy.
Copyright © 2024. Published by Elsevier Inc.
Similar articles
-
Evolving the surveillance and workup of heart transplant rejection: A real-world analysis of the Molecular Microscope Diagnostic System.Am J Transplant. 2022 Oct;22(10):2443-2450. doi: 10.1111/ajt.17087. Epub 2022 May 24. Am J Transplant. 2022. PMID: 35514138
-
Pathologist interrater reliability and clinical implications of elevated donor-derived cell-free DNA beyond heart transplant rejection, on behalf of the GRAfT investigators.J Heart Lung Transplant. 2025 May;44(5):803-812. doi: 10.1016/j.healun.2024.10.006. Epub 2024 Oct 17. J Heart Lung Transplant. 2025. PMID: 39424014
-
The Trifecta Study: Comparing Plasma Levels of Donor-derived Cell-Free DNA with the Molecular Phenotype of Kidney Transplant Biopsies.J Am Soc Nephrol. 2022 Feb;33(2):387-400. doi: 10.1681/ASN.2021091191. Epub 2022 Jan 20. J Am Soc Nephrol. 2022. PMID: 35058354 Free PMC article. Clinical Trial.
-
The utilization of molecular microscope in management of heart transplant recipients in the era of noninvasive monitoring.Clin Transplant. 2023 Dec;37(12):e15131. doi: 10.1111/ctr.15131. Epub 2023 Oct 28. Clin Transplant. 2023. PMID: 37897211 Review.
-
The Molecular Microscope Diagnostic System: Assessment of Rejection and Injury in Heart Transplant Biopsies.Transplantation. 2023 Jan 1;107(1):27-44. doi: 10.1097/TP.0000000000004323. Epub 2022 Dec 8. Transplantation. 2023. PMID: 36508644 Review.
Cited by
-
Evaluation of de novo donor specific antibodies after kidney transplantation in the era of donor-derived cell-free DNA.Front Immunol. 2025 Jan 16;15:1530065. doi: 10.3389/fimmu.2024.1530065. eCollection 2024. Front Immunol. 2025. PMID: 39885988 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
